{"title":"The Monoclonal Antibody Program of the Cuban Institute of Oncology and Radiobiology.","authors":"A Lage","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A Monoclonal Antibody Program was launched at the National Institute of Oncology and Radiobiology (INOR) in Cuba in 1985. Eleven MAbs have been obtained which recognize different leukocyte antigens. Four MAbs a series of reagents raised against different types of cytokeratins, carcino-embryonic antigen and the membrane receptor for Epidermal Growth Factor. These MAbs are especially useful in immunohistochemistry for the study of human tumours, leukemias and lymphomas. Three ultramicro-ELISA systems have being deviced using MAbs. First trials are being made with radioactive MAbs for immunoscintigraphy. The use of anti T-cell MAbs for the prevention of rejection crisis in patients receiving organ transplantation and for the treatment of patient with cutaneous T-cell lymphoma is still mostly a matter for research.</p>","PeriodicalId":77530,"journal":{"name":"Eksperimental'naia onkologiia","volume":"12 6","pages":"26-30, 64"},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eksperimental'naia onkologiia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A Monoclonal Antibody Program was launched at the National Institute of Oncology and Radiobiology (INOR) in Cuba in 1985. Eleven MAbs have been obtained which recognize different leukocyte antigens. Four MAbs a series of reagents raised against different types of cytokeratins, carcino-embryonic antigen and the membrane receptor for Epidermal Growth Factor. These MAbs are especially useful in immunohistochemistry for the study of human tumours, leukemias and lymphomas. Three ultramicro-ELISA systems have being deviced using MAbs. First trials are being made with radioactive MAbs for immunoscintigraphy. The use of anti T-cell MAbs for the prevention of rejection crisis in patients receiving organ transplantation and for the treatment of patient with cutaneous T-cell lymphoma is still mostly a matter for research.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
